Natera price target raised to $145 from $130 at Canaccord

Canaccord analyst Kyle Mikson raised the firm’s price target on Natera to $145 from $130 and keeps a Buy rating on the shares. The firm says its panel discussion on minimal residual disease highlighted Natera’s strong competitive positioning. Experts doubt the accuracy of imaging-based approaches and Natera’s method of MRD-based recurrence monitoring involves a customization step that significantly reduces noise, the analyst tells investors in a research note. Canaccord sees a large addressable market that is underpenetrated.